Prevalence and treatment of venous thromboembolism in patients with solid tumors

Zhao,Huihan; Liang,Fangfang; Ling,Ying; Li,Taijie; Fang,Brister; Deng,Tianxin; Ying,Yanping; He,Yu

doi:10.3892/etm.2022.11679

Prevalence and treatment of venous thromboembolism in patients with solid tumors

Authors:
- Huihan Zhao
- Fangfang Liang
- Ying Ling
- Taijie Li
- Brister Fang
- Tianxin Deng
- Yanping Ying
- Yu He
View Affiliations

Affiliations: Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, Department of Nursing, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, Department of Laboratory Medicine, Wuming Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530199, P.R. China, Clinical Research Unit, UT Southwestern Medical Center, Dallas, TX 75235, United States of America, Department of Records Management, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China
Published online on: November 3, 2022 https://doi.org/10.3892/etm.2022.11679
Article Number: 743
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer‑associated venous thromboembolism (VTE) has exhibited a rising incidence rate. Research focusing on cancer‑associated VTE and current anticoagulation therapy strategies is limited. The present study aimed to investigate the prevalence, characteristics and anticoagulation therapy strategies of cancer‑associated VTE. The study was performed on patients with major solid tumors who were admitted to The First Affiliated Hospital of Guangxi Medical University (Nanning, China) between January 2020 and December 2020. The medical records of the patients' demographic characteristics, disease and treatment were extracted from the medical record data system and reviewed. The prevalence of cancer‑associated VTE was calculated, followed by statistical analysis. Patients who received anticoagulation therapy for cancer‑associated VTE were followed up for 1 year. The characteristics and efficacy of anticoagulation therapy strategies were compared and analyzed. A total of 4,926 patients with major solid tumors (mean age, 55.86±11.97 years) were included in the analysis, of which 117 (2.4%; 117/4,926) were diagnosed with cancer‑associated VTE. Patients with pancreatic cancer exhibited the highest prevalence of VTE (10.2%; 5/49), followed by patients with ovarian cancer (5.8%; 9/156) and lung cancer (3.3; 73/2,237). Multivariate analysis identified hypertension comorbidity [odds ratio (OR), 1.661; 95% CI, 1.031‑2.674; P=0.037)] and cancer stage (OR, 1.266; 95% CI, 1.079‑1.486; P=0.004) as independent risk factors for cancer‑associated VTE. Deep vein thrombosis (DVT) of the lower extremity accounted for 62.0%; 62/100) of all DVTs. Moreover, pulmonary embolism (PE) with lower extremity DVT accounted for 53.5% (23/43) of all PE cases. The majority of cancer‑associated VTE cases (63.2%; 74/117) developed 30 days before or after a cancer diagnosis. In addition, cancer‑associated VTE was dominated by symptomatic VTE (59.8%; 70/117). Only 74.4% (87/117) of patients with VTE received anticoagulant treatment, with a median duration of 79 days. The most common anticoagulant treatment strategies were heparin during hospitalization and direct oral anticoagulants (rivaroxaban) after discharge. The anticoagulants associated with bleeding events were rivaroxaban (4.2%; 3/72) and enoxaparin (1.9%; 1/54). In total, 62.1% (36/58) of the patients received anticoagulant treatment for <90 days. In conclusion, the results indicated that the prevalence of cancer‑associated VTE is common and exhibits numerous characteristics. Rivaroxaban has been widely used in cancer‑associated VTE treatment. However, compliance with long‑term anticoagulant treatment is not adequate at present, while the efficacy and safety of rivaroxaban must be evaluated to improve long‑term medication monitoring and follow‑up among patients with cancer‑associated VTE.

View Figures

View References

1	Di Nisio M, van Es N and Büller HR: Deep vein thrombosis and pulmonary embolism. Lancet. 388:3060–3073. 2016.PubMed/NCBI View Article : Google Scholar
2	Mulder FI, Horváth-Puhó E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, Ay C, Büller HR and Sørensen HT: Venous thromboembolism in cancer patients: A population-based cohort study. Blood. 137:1959–1969. 2021.PubMed/NCBI View Article : Google Scholar
3	Khorana AA, Mackman N, Falanga A, Pabinger I, Noble S, Ageno W, Moik F and Lee AYY: Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 8(11)2022.PubMed/NCBI View Article : Google Scholar
4	Falanga A, Russo L, Milesi V and Vignoli A: Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol. 118:79–83. 2017.PubMed/NCBI View Article : Google Scholar
5	Mahajan A, Brunson A, White R and Wun T: The epidemiology of cancer-associated venous thromboembolism: An update. Semin Thromb Hemost. 45:321–325. 2019.PubMed/NCBI View Article : Google Scholar
6	Fernandes CJ, Morinaga LTK, Alves JLJ, Castro MA, Calderaro D, Jardim CVP and Souza R: Cancer-associated thrombosis: The when, how and why. Eur Respir Rev. 28(180119)2019.PubMed/NCBI View Article : Google Scholar
7	Weitz JI, Haas S, Ageno W, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Nielsen JD, Kayani G, Farjat AE, et al: Cancer associated thrombosis in everyday practice: Perspectives from GARFIELD-VTE. J Thromb Thrombolysis. 50:267–277. 2020.PubMed/NCBI View Article : Google Scholar
8	Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R and Rimm AA: Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 78:285–291. 1999.PubMed/NCBI View Article : Google Scholar
9	Kenmotsu H, Notsu A, Mori K, Omori S, Tsushima T, Satake Y, Miki Y, Abe M, Ogiku M, Nakamura T, et al: Cumulative incidence of venous thromboembolism in patients with advanced cancer in prospective observational study. Cancer Med. 10:895–904. 2021.PubMed/NCBI View Article : Google Scholar
10	Ohashi Y, Ikeda M, Kunitoh H, Sasako M, Okusaka T, Mukai H, Fujiwara K, Nakamura M, Oba MS, Kimura T, et al: Venous thromboembolism in cancer patients: Report of baseline data from the multicentre, prospective cancer-VTE registry. Jpn J Clin Oncol. 50:1246–1253. 2020.PubMed/NCBI View Article : Google Scholar
11	Peng M, Yang S, Li G, Zhang T, Qin X, Shi C, Chang J, Chen M, Chen C, Li B, et al: Solid tumor complicated with venous thromboembolism: A 10-year retrospective cross-sectional study. Clin Appl Thromb Hemost. 27(1076029620975484)2021.PubMed/NCBI View Article : Google Scholar
12	Bao Y, Wan X, Fu J and Wu B: The risk of venous thromboembolism in cancer patients receiving chemotherapy: A meta-analysis with systematic review. Ann Transl Med. 9(277)2021.PubMed/NCBI View Article : Google Scholar
13	Cohen AT, Katholing A, Rietbrock S, Bamber L and Martinez C: Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost. 117:57–65. 2017.PubMed/NCBI View Article : Google Scholar
14	Gurizzan C, Roca E, Faggiano A, Paoli D, Dinatolo E, Masini G, Tomasi C, De Palma G, Metra M, Berruti A and Faggiano P: Rate of venous thromboembolism and atrial fibrillation in a real-world case series of advanced cancer patients: The CaTEV study. J Cardiovasc Med (Hagerstown). 22:444–452. 2021.PubMed/NCBI View Article : Google Scholar
15	Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, et al: Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 38:496–520. 2020.PubMed/NCBI View Article : Google Scholar
16	Centers for Disease Control and Prevention: ICD-10-CM Browser Tool. https://www.cdc.gov/nchs/icd/icd10cm_browsertool.htm. Accessed November 20, 2019.
17	Piñeros M, Parkin DM, Ward K, Chokunonga E, Ervik M, Farrugia H, Gospodarowicz M, O'Sullivan B, Soerjomataram I, Swaminathan R, et al: Essential TNM: A registry tool to reduce gaps in cancer staging information. Lancet Oncol. 20:e103–e111. 2019.PubMed/NCBI View Article : Google Scholar
18	Khorana AA, Francis CW, Culakova E, Kuderer NM and Lyman GH: Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 110:2339–2346. 2007.PubMed/NCBI View Article : Google Scholar
19	Abdol Razak NB, Jones G, Bhandari M, Berndt MC and Metharom P: Cancer-associated thrombosis: An overview of mechanisms, risk factors, and treatment. Cancers (Basel). 10(380)2018.PubMed/NCBI View Article : Google Scholar
20	Sakamoto J, Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, Oi M, Akao M, Kobayashi Y, et al: Cancer-associated venous thromboembolism in the real world-from the COMMAND VTE registry. Circ J. 83:2271–2281. 2019.PubMed/NCBI View Article : Google Scholar
21	Arachchillage DR and Laffan M: Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms. Semin Thromb Hemost. 45:604–611. 2019.PubMed/NCBI View Article : Google Scholar
22	Ahlbrecht J, Dickmann B, Ay C, Dunkler D, Thaler J, Schmidinger M, Quehenberger P, Haitel A, Zielinski C and Pabinger I: Tumor grade is associated with venous thromboembolism in patients with cancer: Results from the Vienna cancer and thrombosis study. J Clin Oncol. 30:3870–3875. 2012.PubMed/NCBI View Article : Google Scholar
23	Rondon AMR, Kroone C, Kapteijn MY, Versteeg HH and Buijs JT: Role of tissue factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost. 45:396–412. 2019.PubMed/NCBI View Article : Google Scholar
24	Donnellan E and Khorana AA: Cancer and venous thromboembolic disease: A review. Oncologist. 22:199–207. 2017.PubMed/NCBI View Article : Google Scholar
25	Frere C: Burden of venous thromboembolism in patients with pancreatic cancer. World J Gastroenterol. 27:2325–2340. 2021.PubMed/NCBI View Article : Google Scholar
26	Khorana AA, Dalal M, Lin J and Connolly GC: Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 119:648–655. 2013.PubMed/NCBI View Article : Google Scholar
27	Ma SQ, Lin Y, Ying HY, Shao YJ, Li XY and Bai CM: Solid malignancies complicated with pulmonary embolism: clinical analysis of 120 patients. Chin Med J (Engl). 123:29–33. 2010.PubMed/NCBI View Article : Google Scholar
28	Huisman MV, Barco S, Cannegieter SC, Le Gal G, Konstantinides SV, Reitsma PH, Rodger M, Vonk Noordegraaf A and Klok FA: Pulmonary embolism. Nat Rev Dis Primers. 4(18028)2018.PubMed/NCBI View Article : Google Scholar
29	Robert-Ebadi H and Righini M: Management of distal deep vein thrombosis. Thromb Res. 149:48–55. 2017.PubMed/NCBI View Article : Google Scholar
30	Caldwell K, Prior SJ, Kampmann M, Zhao L, McEvoy S, Goldberg AP and Lal BK: . Upper body exercise increases lower extremity venous blood flow in deep venous thrombosis. J Vasc Surg Venous Lymphat Disord. 1:126–133. 2013.PubMed/NCBI View Article : Google Scholar
31	Shimizu Y, Kamada H, Sakane M, Aikawa S, Mutsuzaki H, Tanaka K, Mishima H, Ochiai N and Yamazaki M: A novel apparatus for active leg exercise improves venous flow in the lower extremity. J Sports Med Phys Fitness. 56:1592–1597. 2016.PubMed/NCBI
32	Shalhoub J, Lawton R, Hudson J, Baker C, Bradbury A, Dhillon K, Everington T, Gohel MS, Hamady Z, Hunt BJ, et al: Compression stockings in addition to low-molecular-weight heparin to prevent venous thromboembolism in surgical inpatients requiring pharmacoprophylaxis: the GAPS non-inferiority RCT. Health Technol Assess. 24:1–80. 2020.PubMed/NCBI View Article : Google Scholar
33	Suzuki T, Fujino S, Inaba S, Yamamura R, Katoh H, Noji Y, Yamaguchi M and Aoyama T: Venous thromboembolism in patents with lung cancer. Clin Appl Thromb Hemost. 26(1076029620977910)2020.PubMed/NCBI View Article : Google Scholar
34	Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, Fanikos J, Fenninger RB, Fogerty AE, Gao S, et al: NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018. J Natl Compr Canc Netw. 16:1289–1303. 2018.PubMed/NCBI View Article : Google Scholar
35	Fuentes HE, McBane RD II, Wysokinski WE, Tafur AJ, Loprinzi CL, Murad MH and Riaz IB: Direct oral factor Xa inhibitors for the treatment of acute cancer-associated venous thromboembolism: A systematic review and network meta-analysis. Mayo Clin Proc. 94:2444–2454. 2019.PubMed/NCBI View Article : Google Scholar
36	Ay C, Beyer-Westendorf J and Pabinger I: Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. Ann Oncol. 30:897–907. 2019.PubMed/NCBI View Article : Google Scholar